期刊文献+

化学发光免疫法检测血清CEA,CA199和CA125水平在恶性肿瘤诊断中的意义(英文) 被引量:12

Significance of determination of CEA,CA199 and CA125 in patients with malignant tumor by chemiluminescence immunoassay (CLIA)
下载PDF
导出
摘要 目的探讨血清中CEA,CA199和CA125在恶性肿瘤中的临床应用价值。方法应用全自动化学发光免疫方法检测50例正常人,40例良性肿瘤患者及214例恶性肿瘤患者(其中肝癌40例、胃癌30例、结直肠癌42例,卵巢癌30例、胰腺癌20例、肺癌52例)血清中CEA,CA199和CA125水平并进行比较分析。结果肝癌、胃癌、结直肠癌、卵巢癌、胰腺癌、肺癌血清CEA,CA199和CA125含量显著高于正常对照组及良性肿瘤组(P<0.01),CEA,CA199和CA125单检的阳性率分别为50.0%,50.9%和50.4%,联检总的阳性率为85.5%。结论血清CEA,CA199和CA125联合应用于恶性肿瘤的诊断及提高总的检出率具有价值。 Objective: To explore the clinical values of serum CEA?CA199 and CA125 in diagnosing malignant tumor. Methods: Levels of CEA, CA199 and CA125 in serum were measured by chemiluminescence immunoassay (CLIA) in 50 normal persons, 40 patients with benign tumors and 214 patients with malignant tumors (40 cases with primary liver cancer, 30 cases with gastric carcinoma, 42 cases with colorectal carcinoma, 30 cases with ovarian carcinoma, 20 cases with pancreatic carcinoma and 52 cases with lung carcinoma). Results: In patients with liver cancer, gastric carcinoma, colorectal carcinoma, ovarian carcinoma, pancreatic carcinoma and lung carcinoma, the contents of serum CEA, CA199 and CA125 were significantly higher than that in normal persons and patients with benign tumors (P <0.01). The serum CEA, CA199 and CA125 positive rate were 50.0%, 50.9%, 50.4% respectively, the total positive rate was 85.5%. Conclusions: Combined measurement of CEA, CA199 and CA125 is useful for the diagnosis and achieving higher positive in patients with malignant tumor.
出处 《中国现代医学杂志》 CAS CSCD 2004年第16期21-23,26,共4页 China Journal of Modern Medicine
关键词 化学发光免疫法 恶性肿瘤 CEA CA199 CA125 chemiluminescence immunoassay (CLIA) malignant tumor CEA CA199 CA125
  • 相关文献

参考文献8

  • 1Roulston JE, Leonard RCE. Serological tumor markers Churchill Livingstone[M]. Black well scioxford, 1993: 11.
  • 2Haglunde Lundin J, Kunsela D, et al. CA242 a new tumor markers for Pancreatic cancer[J]. Br J cancer, 1994, 70: 487.
  • 3Pittaway DE. CA125 in women with emdometriosis[J]. Obstet Gynecol Clin North Am, 1989, 16(1): 237-252.
  • 4Sun WH, Serum CA125, the CA242 monitors the malignant tumor the illness, 1989, 16(1): 237-252.
  • 5Michael J, Conor J, Zauber A, Gottlieb LS, Winawer SJ, Precursors of colorectal carcinoma[J]. Cancer, 1992, 70(5): 1317-1327.
  • 6Favero GD, Fabris C, Plebani M, Panucci A, Piccoli A, Perobelli L et al. Ca199 and carcinoe mbryonic antigen inpancreatin cancer diagnosis[J]. Cancer, 1986, 57(8): 1576-1579.
  • 7YAO H, LIN ME, Serum CA125, CA199, CA50 levels to the diagnosis value to digestive system malignant tumor [J]. Shijie Huaren Xaiohua Zazhi, 1998, 6: 12. Chinese
  • 8HU M, YINL, WEI YJ. CEA, 17-1A of Related colorectal cancer immunity treatment[J]. Zhongguo Xiandai Yixue Zazhi, 2002,12(8): 6-4. Chinese

同被引文献61

引证文献12

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部